Recipharm
Bookmark
ShareCopied to clipboardRecipharm is a company. It is a private company in Stockholm, Sweden. It was founded in 1995 and it is part of the Health Care sector, specifically in the Pharmaceuticals industry.
Key facts
- city: Stockholm
- country: Sweden
- employees: Try Pro to see estimate
- revenues: Try Pro to see estimate
- company type: private
- sector: Health Care
- industry: Pharmaceuticals
- foundation year: 1995
- ESG score: Try Pro to see estimate
See more facts
Extract data
Download datasets about Recipharm:
Dataset of stocks from Recipharm:
Recipharm is one of the companies in Sweden, companies in Pharmaceuticals, companies in Health Care, companies in Stockholm and 3,456,808 companies in our database.
Talking Points
- Recipharm | CDMO | Pharmaceutical Development & Manufacturing
- Recipharm is a world leading CDMO. Supporting customers in bringing innovations to market, from early stage development to commercial manufacturing.
- The brightest minds in the CDMO industry. | About Recipharm: Recipharm is a leading contract development and manufacturing organisation (CDMO) headquartered in Stockholm, Sweden. We operate development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and are continuing to grow and expand ...
- Drug delivery devices
- Bespak by Recipharm is an expert in market-leading design, development, and manufacturing services for drug delivery devices for the global pharma market.
- We are a leading developer and manufacturer of premium drug delivery devices, now part of Recipharm. | About Bespak: Bespak is the name behind some of the most widely used and trusted inhalation devices in the world. We are a global market leader providing pharmaceutical companies around the world with inhaler and auto-injector technologies and development ...
- Formulation development
- We offer pharmaceutical formulation development services for conventional dosage forms, but also for specialised forms, including complex modified release.